advertisement

---

De Moraes CG 10

Showing records 1 to 10 | Display all abstracts from De Moraes CG

96133 Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial
De Moraes CG
JAMA ophthalmology 2022; 140: 11-18

---

96414 Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results
Hark LA
Current Eye Research 2021; 46: 1597-1604

---

96133 Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial
John SWM
JAMA ophthalmology 2022; 140: 11-18

---

96414 Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results
Tan CS; Kresch YS
Current Eye Research 2021; 46: 1597-1604

---

96133 Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial
Williams PA
JAMA ophthalmology 2022; 140: 11-18

---

96414 Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results
De Moraes CG
Current Eye Research 2021; 46: 1597-1604

---

96133 Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial
Blumberg DM
JAMA ophthalmology 2022; 140: 11-18

---

96414 Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results
Horowitz JD
Current Eye Research 2021; 46: 1597-1604

---

96133 Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial
Cioffi GA; Liebmann JM
JAMA ophthalmology 2022; 140: 11-18

---

96414 Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results
Park L; Auran JD; Gorroochurn P; Stempel S; Maruri SC; Besagar S; Saaddine JB; Lambert BC; Pizzi LT; Sapru S; Price S; Williams OA; Cioffi GA; Liebmann JM
Current Eye Research 2021; 46: 1597-1604

---